GALECTIN THERAPEUTICS INC. Operating Lease, Right-of-Use Asset, Amortization Expense
GALECTIN THERAPEUTICS INC. (GALT) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $53.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-03-31
- GALECTIN THERAPEUTICS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-12-31 was $10.00K, a 11.11% increase year-over-year.
- GALECTIN THERAPEUTICS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-09-30 was $9.00K, a 12.50% increase year-over-year.
- GALECTIN THERAPEUTICS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-06-30 was $9.00K.
- GALECTIN THERAPEUTICS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-03-31 was $9.00K, a 71.88% decline year-over-year.
- GALECTIN THERAPEUTICS INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $53.00K, a 43.24% increase from fiscal 2024.
- GALECTIN THERAPEUTICS INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $37.00K, a 12.12% increase from fiscal 2023.
- GALECTIN THERAPEUTICS INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $33.00K, a 3.13% increase from fiscal 2022.
- GALECTIN THERAPEUTICS INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $32.00K, a 21.95% decline from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $53.00K 10-K · filed 2026-03-31 | |||
| 2024-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $19.00K derived: sum of 2 quarters · filed 2026-03-31 | $28.00K derived: sum of 3 quarters · filed 2026-03-31 | $37.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $18.00K derived: sum of 2 quarters · filed 2024-11-14 | $27.00K 10-Q · filed 2024-11-14 | $36.00K derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | $9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $18.00K 10-Q · filed 2024-08-13 | $27.00K derived: sum of 3 quarters · filed 2025-03-31 | $35.00K derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | $9.00K 10-Q · filed 2024-05-15 | $18.00K derived: sum of 2 quarters · filed 2025-03-31 | $26.00K derived: sum of 3 quarters · filed 2025-03-31 | $10.00K derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $17.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.00K derived: sum of 3 quarters · filed 2025-03-31 | $33.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$8.00K derived: sum of 2 quarters · filed 2024-11-14 | $24.00K 10-Q · filed 2024-11-14 | $32.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $16.00K 10-Q · filed 2024-08-13 | $24.00K derived: sum of 3 quarters · filed 2024-08-13 | $31.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $32.00K 10-Q · filed 2024-05-15 | $40.00K derived: sum of 2 quarters · filed 2024-05-15 | $47.00K derived: sum of 3 quarters · filed 2024-05-15 | $54.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $15.00K derived: sum of 2 quarters · filed 2024-03-29 | $22.00K derived: sum of 3 quarters · filed 2024-03-29 | $32.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $14.00K derived: sum of 2 quarters · filed 2023-11-13 | $24.00K 10-Q · filed 2023-11-13 | $35.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $17.00K 10-Q · filed 2023-08-14 | $28.00K derived: sum of 3 quarters · filed 2023-08-14 | $38.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $10.00K 10-Q · filed 2023-05-15 | $21.00K derived: sum of 2 quarters · filed 2023-05-15 | $31.00K derived: sum of 3 quarters · filed 2023-05-15 | $41.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $21.00K derived: sum of 2 quarters · filed 2023-03-30 | $31.00K derived: sum of 3 quarters · filed 2023-03-30 | $41.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $20.00K derived: sum of 2 quarters · filed 2022-11-14 | $30.00K 10-Q · filed 2022-11-14 | $39.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $20.00K 10-Q · filed 2022-08-15 | $29.00K derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | $10.00K 10-Q · filed 2022-05-16 | $19.00K derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $36.00K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $27.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |